JZP-110 PHASE 3 CLINICAL PROGRAM STARTS
JZP-110 is an investigational wake-promoting agent being developed as a treatment for EDS in adult patients with narcolepsy or with OSA. Jazz has worldwide rights to JZP-110, excluding certain jurisdictions in Asia where SK Biopharmaceuticals Co., Ltd retains rights.
JAZZ IN THE NEWS
CEO Bruce Cozadd interview with Life Sciences Leader: “From Foundation, To Darkest Days, To Finest Hour — The Jazz Pharmaceuticals Success Story.”
EXPANDED ACCESS PROGRAM
Jazz Pharmaceuticals continues to accrue patients in the defibrotide treatment investigational new drug (T-IND) study in patients diagnosed with hepatic VOD.